Mogamulizumab-Kpkc (1 brand name, 1 dosage form, 1 route)
Available dosage forms: INJECTABLE.
Routes of administration: INJECTION.
Brand Names
- POTELIGEO
Indications and Usage
POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
Contraindications
None.
Adverse Reactions
The following serious adverse reactions are discussed in greater detail in other sections of the labeling: Dermatologic Toxicity [see Warnings and Precautions (5.1) ]. Infusion Reactions [see Warnings and Precautions (5.2) ]. Infections [see Warnings and Precautions (5.3) ]. Autoimmune Complications [see Warnings and Precautions (5.4) ]. Complications of Allogeneic HSCT after POTELIGEO [see Warnings and Precautions (5.5) ].
Mechanism of Action
Mogamulizumab-kpkc is a defucosylated, humanized IgG1 kappa monoclonal antibody that binds to CCR4, a G protein-coupled receptor for CC chemokines that is involved in the trafficking of lymphocytes to various organs. Non-clinical in vitro studies demonstrate mogamulizumab-kpkc binding targets a cell for antibody-dependent cellular cytotoxicity (ADCC) resulting in depletion of the target cells. CCR4 is expressed on the surface of some T-cell malignancies and is expressed on regulatory T-cells (Treg) and a subset of Th2 T-cells.